Data are n (%). | PBO + FBX | LESU200 + FBX | LESU400 + FBX |
---|---|---|---|
N=109 | N=106 | N=109 | |
Patients experiencing any TEAE | 79 (72.5%) | 87 (82.1%) | 90 (82.6%) |
Patients with serious TEAEs | 10 (9.2%) | 6 (5.7%) | 9 (8.3%) |
Patients with any renal-related AEs | 6 (5.5%) | 9 (8.5%) | 11 (10.1%) |
Patients with serious renal-related AEs | 1 (0.9%) | 0 (0%) | 2 (1.8%) |
Patients with kidney stones | 4 (3.7%) | 1 (0.9%) | 2 (1.8%) |
Patients with ≥2.0x increase in sCr | 0 (0%) | 3 (2.8%) | 6 (5.5%) |
Number (%) sCr elevations resolved at last study visit | – | 2/3 (67%) | 6/7 (86%) |